Parallel track: Where should it intersect science?

Article Abstract:

There are conflicting opinions on how clinical trials testing the effectiveness of various drugs in patients with AIDS should be conducted. The data from the clinical trials must be solid. However, as many drugs as possible should be available to the patients. A possible solution to the conflict is parallel tracking, so that drugs are available to patients at the same time the clinical trials are being conducted to determine their effectiveness. The patient's physician would have to agree to reveal information about the effects of the drug in the patient to those running the clinical trials. A conference entitled ''Expected Access to Unproven Pharmaceuticals: Risk, Regulation, and Personal Autonomy'' was held in November 1990. There are various opinions on the effectiveness of parallel tracking. It is felt by some that parallel tracking raises as many questions as it answers and it is not known how much data should be collected on the parallel track. However, parallel tracking may revolutionize how drugs for life-threatening diseases are tested. Parallel tracking would make drugs available to patients who cannot participate in clinical trials because they aren't eligible under the requirements of the trial or because they live far from the trial center. Although parallel tracking has received a lot of publicity, it has not been formally accepted. The drug dideoxyinosine (ddI) has been available to patients with AIDS through expanded access, which is similar to parallel tracking, except little data is collected about the drug. This latter process is wasteful in that it does not attempt to collect data and learn what can be learned about the side effects, safety and effectiveness of the drug. One hundred patients had been taking ddI in clinical trials, but with expanded access, approximately 14,000 patients could obtain the drug. It is suggested that a type of clinical trial be held that combines parallel track and expanded access. These would be large simple trials, consisting of almost anyone who wants to participate, with simple data concerning the effectiveness being collected from the physicians. It must be remembered that drugs that are available but are not officially approved have increased risk of toxicity and side effects. (Consumer Summary produced by Reliance Medical Information, Inc.)

Conferences, meetings and seminars, AIDS (Disease), Clinical pharmacology

---

Current problems and the future of antiretroviral drug trials

Article Abstract:

Suboptimal antiretroviral therapies continue to be used in clinical trials for a variety of reasons including regulatory requirements and the financial interests of pharmaceutical companies. Recommendations for ensuring that all patients receive optimal therapies are provided.

Management, Clinical trials, HIV infection, HIV infections, Ethical aspects, Human experimentation in medicine, Human medical experimentation, Pharmaceutical research

---

Similar abstracts:

• Abstracts: The influence of thermoplastic film interleaving on the interlaminar shear strength and mode I fracture of laminated composites
• Abstracts: Neglected neurotoxicants. The effect of deprenyl (selegiline) on the natural history of Parkinson's disease. Reversal of experimental Parkinsonism by lesions of the subthalamic nucleus
• Abstracts: Molecular targets for AIDS therapy. The shrewd grasp of RNA polymerase
• Abstracts: New methods of drug delivery. Identification of an inhibitor of neovascularization from cartilage. Stand and deliver: getting peptide drugs into the body

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.